Kempharm(KMPH) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Zevra Reports First Quarter 2025 Financial Results and Corporate Update Q1 2025 net revenue of $20.4 million, driven by product net revenue of$17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company's commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May. 13, 2025 -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a comm ...